Algorae Locks in Deal With $1.7B Torrent to Fast-Track Generic Drugs to Market
Algorae Pharmaceuticals (ASX: 1AI) has secured an Algorae Torrent Pharma License Agreement covering two generic prescription molecules for the Australian and New Zealand markets, marking the company's sixth commercial deal through its AlgoraeRx subsidiary.
Key Takeaways
- Algorae Pharmaceuticals has executed a Licence and Supply Agreement with Torrent Pharmaceuticals, the 5th largest player in the Indian Pharmaceuticals Market with annual revenues of approximately AUD$1.68 billion, for two generic prescription molecules targeting Australia and New Zealand.
- The agreement follows a two-phase commercialisation structure, with Phase 1 targeting products with existing regulatory registrations and Phase 2 covering new TGA registrations for longer-term pipeline development.
- This represents Algorae's sixth commercial agreement executed through its wholly owned subsidiary AlgoraeRx Pty Ltd, supporting the company's dual-track strategy of near-term revenue generation alongside AI-driven drug discovery via the AlgoraeOS platform.
- Torrent Pharmaceuticals brings significant manufacturing credibility, operating 8 facilities of which 5 hold USFDA approval and maintaining a presence in over 50 countries, which de-risks supply chain execution for Algorae.
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.